DUBLIN – Prosensa Holding NV hopped off the rollercoaster it's been traveling on for more than a year by agreeing to a cash acquisition deal with Biomarin Pharmaceutical Inc. worth about $680 million up front, with another $160 million to come in two near-term regulatory milestones.